AU1385801A - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
AU1385801A
AU1385801A AU13858/01A AU1385801A AU1385801A AU 1385801 A AU1385801 A AU 1385801A AU 13858/01 A AU13858/01 A AU 13858/01A AU 1385801 A AU1385801 A AU 1385801A AU 1385801 A AU1385801 A AU 1385801A
Authority
AU
Australia
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13858/01A
Inventor
Anthony J. Taylor
David A. Wyatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU1385801A publication Critical patent/AU1385801A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
AU13858/01A 1999-10-21 2000-10-19 Pharmaceutical formulations Abandoned AU1385801A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9924992 1999-10-21
GBGB9924992.2A GB9924992D0 (en) 1999-10-21 1999-10-21 Pharmaceutical aerosol formulations
PCT/EP2000/010306 WO2001028535A2 (en) 1999-10-21 2000-10-19 Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate

Publications (1)

Publication Number Publication Date
AU1385801A true AU1385801A (en) 2001-04-30

Family

ID=10863173

Family Applications (2)

Application Number Title Priority Date Filing Date
AU13858/01A Abandoned AU1385801A (en) 1999-10-21 2000-10-19 Pharmaceutical formulations
AU11411/01A Abandoned AU1141101A (en) 1999-10-21 2000-10-19 Pharmaceutical aerosol formulations comprising s-salmeterol

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU11411/01A Abandoned AU1141101A (en) 1999-10-21 2000-10-19 Pharmaceutical aerosol formulations comprising s-salmeterol

Country Status (3)

Country Link
AU (2) AU1385801A (en)
GB (1) GB9924992D0 (en)
WO (2) WO2001028535A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020387A1 (en) * 2000-08-31 2002-06-24 Glaxo Group Ltd USE OF A COMBINATION OF SALMETEROL AND FLUTICASONE
GB0021927D0 (en) * 2000-09-07 2000-10-25 Glaxo Group Ltd Use of pharmaceutical combination
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
GB0124523D0 (en) * 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
JP2006528228A (en) * 2003-05-22 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト Salmeterol and ciclesonide combination
WO2007011743A2 (en) 2005-07-14 2007-01-25 Lipothera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
TR201000685A2 (en) * 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Pharmaceutical preparations containing salmeterol and fluticasone.
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CN1142798C (en) * 1995-04-14 2004-03-24 葛兰素惠尔康公司 Metered dose inhaler for slameterol
US6254882B1 (en) * 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol

Also Published As

Publication number Publication date
AU1141101A (en) 2001-04-30
WO2001028535A2 (en) 2001-04-26
WO2001028514A1 (en) 2001-04-26
WO2001028535A3 (en) 2002-01-10
GB9924992D0 (en) 1999-12-22

Similar Documents

Publication Publication Date Title
AU1071301A (en) Pharmaceutical compounds
AU3192700A (en) Medicinal compositions
HUP0202235A3 (en) Preserved pharmaceutical formulations
AU3556400A (en) Pharmaceutical compositions
AU2005300A (en) Medicinal compositions
AU4328800A (en) Pharmaceutical formulation
AU1887401A (en) Medicinal composition
AU6715600A (en) Pharmaceutical formulations
AU6460400A (en) Pharmaceutical compositions
AU4977300A (en) Pharmaceutical formulations
AU1385801A (en) Pharmaceutical formulations
AU6460200A (en) Pharmaceutical compositions
AU5722900A (en) Pharmaceutical compounds
AU3839900A (en) Pharmaceutical formulation
AU6460100A (en) Pharmaceutical compositions
AU6460300A (en) Pharmaceutical compositions
AU4914400A (en) Novel pharmaceutical composition
AU1388501A (en) Pharmaceutical formulation
GB9930578D0 (en) Pharmaceutical formulations
GB9906126D0 (en) Pharmaceutical formulations
AU5182099A (en) Pharmaceutical formulation
AU4504201A (en) Drug preparations
AU2001230490A1 (en) Pharmaceutical formulation
GB9903177D0 (en) Pharmaceutical formulations
GB9905983D0 (en) Pharmaceutical formulations

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase